Invivyd (Nasdaq:IVVD) - Aandelenkoers, Nieuws & Analyse

IVVD Overzicht aandelen

IVVD fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 99.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 72.16% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft minder dan 1 jaar cash runway

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $84M )

Invivyd, Inc. Concurrenten

X4 Pharmaceuticals

NasdaqCM:XFOR

US$57.6m

Connect Biopharma Holdings

NasdaqGM:CNTB

US$55.3m

Prelude Therapeutics

NasdaqGS:PRLD

US$52.2m

BioAtla

NasdaqGM:BCAB

US$75.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Invivyd
Historische aandelenkoersen
Huidige aandelenkoers	US$0.70
52 Week Hoogtepunt	US$5.20
52 Week Laag	US$0.69
Bèta	0.66
11 maand verandering	-28.00%
3 maanden verandering	-45.63%
1 Jaar Verandering	-52.93%
33 jaar verandering	-97.21%
5 jaar verandering	n/a
Verandering sinds IPO	-96.64%

Recent nieuws en updates

Recent updates

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

Rendement voor aandeelhouders

	IVVD	US Biotechs	US Markt
7D	-7.1%	2.5%	2.2%
1Y	-52.9%	16.1%	31.6%

Rendement versus industrie: IVVD presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.1 % opleverde.

Rendement versus markt: IVVD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement	17.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van IVVD is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van IVVD is het afgelopen jaar gedaald van 23% naar 18%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2020	95	Bill Duke	invivyd.com

Invivyd, Inc., een biofarmaceutisch bedrijf in een commerciële fase, richt zich op het ontdekken, ontwikkelen en op de markt brengen van op antilichamen gebaseerde oplossingen voor infectieziekten in de Verenigde Staten. Het bedrijf ontwikkelde INVYMAB, een platform dat virale surveillance en voorspellende modellering combineert met geavanceerde antilichaam-engineering. De pijplijn bevat PEMGRADA (pemivibart) injectie, een onderzoeksmonoklonaal antilichaam (mAb) met verlengd halfleven voor de preventie van COVID-19 bij volwassenen en adolescenten; VYD2311, een mAb-kandidaat die zich in preklinische studies bevindt voor de preventie of behandeling van COVID-19; en adintrvimab, dat zich in klinische studies in fase 3 bevindt voor de preventie of behandeling van COVID-19.

Invivyd, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Invivyd zich tot de beurswaarde?
IVVD fundamentele statistieken
Marktkapitalisatie	US$83.90m
Inkomsten(TTM)	-US$225.14m
Inkomsten(TTM)	US$11.56m

7.3x

P/S-verhouding

-0.4x

Koers/Winstverhouding

Is IVVD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IVVD resultatenrekening (TTM)
Inkomsten	US$11.56m
Kosten van inkomsten	US$894.00k
Brutowinst	US$10.67m
Overige uitgaven	US$235.81m
Inkomsten	-US$225.14m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.88
Brutomarge	92.27%
Nettowinstmarge	-1,946.87%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde IVVD op de lange termijn?

Bekijk historische prestaties en vergelijking

IVVD Overzicht aandelen

Beloningen

Risicoanalyse

Invivyd, Inc. Concurrenten

NasdaqCM:XFOR

US$57.6m

NasdaqGM:CNTB

US$55.3m

NasdaqGS:PRLD

US$52.2m

NasdaqGM:BCAB

US$75.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Recent updates

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

Less than half of directors are independent

Adagio names David Hering as permanent CEO and Director

Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors

Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index

Adagio Therapeutics, Inc. Elects Class I Directors

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

No longer forecast to breakeven